Lazard Asset Management
FDMT icon

Lazard Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Lazard Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed – – 2383
2024
Q4 		$0 Hold
26
– – ﹤0.01% 2359
2024
Q3 		$0 Sell
26
-64
-71% -$1.06K ﹤0.01% 2316
2024
Q2 		$1K Sell
90
-1,443
-94% -$36.2K ﹤0.01% 2142
2024
Q1 		$48K Sell
1,533
-7,981
-84% -$204K ﹤0.01% 1722
2023
Q4 		$192K Buy
9,514
+7,221
+315% +$95K ﹤0.01% 1397
2023
Q3 		$28K Buy
2,293
+103
+5% +$1.72K ﹤0.01% 2043
2023
Q2 		$38K Buy
2,190
+671
+44% +$12.4K ﹤0.01% 1913
2023
Q1 		$25K Sell
1,519
-660
-30% -$12.8K ﹤0.01% 1999
2022
Q4 		$48K Buy
+2,179
New +$33.7K ﹤0.01% 1836

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lazard Asset Management's FDMT Position: Q1 2025 in Review

Lazard Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 26 shares.

Lazard Asset Management first reported a position in FDMT in Q4 2022 and held it in 9 quarters. The position peaked at $192K in Q4 2023. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Lazard Asset Management reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 26 4D Molecular Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's 4D Molecular Therapeutics position peaked at $192K in Q4 2023.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.